Objectives
To assess the effectiveness of drug therapy for treating symptoms of anxiety in adults with a progressive life-limiting illness who are thought to be in their last year of life.
Search methods
We ran the searches for this update to May 2016. We searched the CENTRAL, MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), PsychLIT (Silver Platter) and PsycINFO (Ovid). We searched seven trials registers and seven pharmaceutical industry trials registers. We handsearched the conference abstracts of the European Association of Palliative Care.
Selection criteria
Randomised controlled trials which examined the effect of drug therapy for the treatment of symptoms of anxiety in adult palliative care patients, that is, people with a known progressive life-limiting illness that is no longer responsive to curative treatment, including advanced heart, respiratory and neurological diseases (including dementia). Comparator treatments included placebo; another drug therapy or different dose schedule; or a non-drug intervention such as counselling, cognitive behaviour therapies or relaxation therapies.
Data collection and analysis
Two review authors independently screened titles and abstracts to identify potentially relevant papers for inclusion in the review. We sought full-text reports for all papers retained at this stage and two reviews authors independently assessed these for inclusion in the review. We planned to assess risk of bias and extract data including information on adverse events. We planned to assess the evidence using GRADE and to create a 'Summary of findings' table.
Main results
In this update, we identified 707 potentially relevant papers and of these we sought the full-text reports of 10 papers. On examination of these full-text reports, we excluded eight and two are awaiting classification as we have insufficient information to make a decision. Thus, in this update, we found no studies which met our inclusion criteria. For the original review, we identified, and then excluded, the full-text reports of six potentially relevant studies. For the 2012 update, we sought, and excluded, two full-text reports. Thus, we found no studies that assessed the effectiveness of drugs to treat symptoms of anxiety in palliative care patients.
Authors' conclusions
There is a lack of evidence to draw a conclusion about the effectiveness of drug therapy for symptoms of anxiety in adult palliative care patients. To date, we have found no studies that meet the inclusion criteria for this review. We are awaiting further information for two studies which may be included in a future update. Randomised controlled trials which assess management of anxiety as a primary endpoint are required to establish the benefits and harms of drug therapy for the treatment of anxiety in palliative care.
Background
Anxiety or worry is a common problem for people who have an illness which is getting worse and are in the last year of their life. People may be anxious for many reasons. These reasons include being worried about pain and treatment, having to rely on other people to help them and having to face death. Anxiety can make it difficult for people to cope with their illness. Anxiety can make other problems worse and harder to manage, problems such as pain or feeling short of breath. For people who are nearing the end of their life due to illness, it is important to reduce their worry if possible. The use of some medicines may help to reduce anxiety. However, anxiety in people who are nearing the end of life has not be studied very much. People with anxiety often do not have their anxiety properly treated.
We searched for studies which looked at how good medicines were at reducing worry in adults nearing the end of their life. We were interested in studies that compared use of a medicine to no medicine, another medicine or a different dose of that medicine, or treatments such as talking to someone or relaxation therapy. We were interested in studies that measured anxiety. We were interested in trials designed to ensure that participants had an equal chance of receiving any of the treatments being tested in each trial. This review was first done in 2004 and updated in 2012. This is the second update. We searched to May 2016 for studies to include in this review.
Key results
We found no studies to include in this review. No studies were found for the original 2004 review or for the 2012 update. There is a lack of studies assessing the effect of drugs on reducing anxiety in adults who are nearing the end of their life. We found two relevant studies which may be included in a future update, but we need more information before we can make a judgement. Anxiety can have a big impact on how a person can cope with their illness, and we therefore need to know how to reduce their anxiety. Good-quality studies on how to reduce anxiety are needed.
Background
Description of the condition This is the second update of the review "Drug therapy for anxiety in adult palliative care patients" originally published in Issue 1, 2004 (Jackson 2004 ) of the Cochrane Library and published as a first update in Issue 10, 2012 (Candy 2012).
Anxiety can be an intractable and crippling condition. It impacts on the person's ability to cope emotionally and to function socially, and may make physical symptoms more difficult to manage (Spencer 2010). In the advanced stages of a progressive, life-limiting illness it may also manifest with concomitant depression and result in the person experiencing even greater difficulties (Mitchell 2011; Wilson 2007) . The symptoms of anxiety include feelings of apprehension, fear, irritability and tension. Cognitively, anxiety manifests itself as excessive worry or difficulty concentrating. Behavioural symptoms involve avoidant or compulsive tendencies, and physical and somatic symptoms include diarrhoea, sweating, restlessness, fatigue, and insomnia. People may also present with more acute symptoms including palpitations, tachycardia, and shortness of breath (Thielking 2003) . Anxiety is a term for a number of disorders, specifically generalised anxiety disorders (GAD), substance-induced anxiety, adjustment disorders, obsessive-compulsive disorders, specific phobias such as in response to medical interventions, panic disorders and post-traumatic stress disorder (DSM-5 2013) . GAD and panic disorder were found in one study to be the most common anxiety disorders in advanced disease (Wilson 2007) . The importance of a holistic approach to managing all symptoms including anxiety has been reaffirmed by frameworks around palliative and end of life care including Ambitions for Palliative and End of Life Care (National Palliative and End of Care 2015) and National Institute for Health and Care Excellence (NICE) guidance on end of life care (NICE 2011a).
In people with a progressive life-limiting illness, anxiety can be a natural reaction to the extraordinary psychological and physical challenges to be faced including the prognostic and treatment uncertainties often associated with the situation. The prevalence of symptoms of excessive anxiety is under researched, but it is one of the most common reasons for a psychiatric consultation in this patient group (Roth 2007) . Anxiety can increase because of a broad range of concerns faced, such as how well symptoms will be managed, increasing dependency on other people, increased social isolation, confrontation with existential issues, and a growing inability to support and be with family and friends. Anxiety may also occur as the result of poorly controlled symptoms, such as pain, or the use of medications. Despite these known risks, anxiety in terminally ill people is underdiagnosed and undertreated, and is less extensively researched than depression (Kolva 2011; Wilson 2007) .
One of the challenges in palliative care is to distinguish between excessive or maladaptive anxiety, and normal distress. There are numerous causes; in particular, it has been highly correlated with uncontrolled pain (Payne 1995). In addition, many studies looking at psychiatric states in people with a life-limiting diagnosis do not clearly separate their assessments of depression and anxiety states or define clearly their study populations with respect to where a person is on their illness journey. This makes it more difficult to identify if anxiety is associated with specific stages in an illness journey, such as the palliative phase.
Anxiety may be a manifestation of a change in metabolic state such as hypoxia or hypoglycaemia, or in the dying phase (last 48 hours of life) as part of the result of multiple organ failure. Certain medications commonly used in caring for people near the end of life may produce symptoms that can be confused with anxiety, for example, akathisia or motor restlessness. These include phenothiazines (e.g. prochlorperazine), butyrophenones (e.g. haloperidol), methotrimeprazine and metoclopramide. Abrupt discontinuation of certain substances can also lead to withdrawal and precipitate an anxiety state, for instance alcohol, nicotine, anticonvulsants, benzodiazepines, clonidine, corticosteroids, opioids and sedative-hypnotics (Maguire 1993) . Numerous other medications and 77 Drug therapy for symptoms associated with anxiety in adult palliative care patients substances have been associated with anxiety symptoms and, therefore, a thorough medication history should always precede changes in a drug therapy regimen (Jackson 2000) .
Description of the intervention
While there are clinical guidelines for the treatment of clinically significant anxiety (Baldwin 2005; NICE 2011b; NICE 2015 ) , few are specific to palliative care where treatments may need to be different because of the added psychological and physical burden of living with a terminal disease (National Consensus Project 2009; NICE 2004; NICE 2015) . Treatment in palliative care can include behavioural techniques, such as cognitive behavioural therapy (CBT) (Moorey 2009 ), and drug therapy. In deciding on treatment options, the clinician has to consider whether a person has both sufficient energy to engage with non-pharmacological interventions and the time needed to establish the benefit of such interventions. In deciding whether a pharmacological approach may be useful, the severity of the person's symptoms and the degree to which they interfere with overall function and well-being are important factors to consider. In addition, the clinician needs to assess whether the person has compromised hepatic and renal function, and must also consider the potential adverse effects of the drug therapy. Short-acting benzodiazepines, such as lorazepam and oxazepam, are often the drugs of choice in terminally ill people (Breitbart 1996; Henderson 2006; Noyes 1998; Roth 2007) . However, they may not be suitable for everyone because of adverse effects such as excessive sedation and confusion, which are associated with an increased risk of falls. Furthermore, if benzodiazepines are given for longer than a few weeks, there is the potential risk of physical dependency. The palliative care literature lists a variety of other potentially useful agents in the management of anxiety including antidepressants, buspirone, chlorpromazine, haloperidol, hydroxyzine, levomepromazine, ketamine and atypical antipsychotic drugs (e.g. olanzapine, risperidone) (Khojainova 2002; Mintzer 2001 ).
How the intervention might work
This review explores the evidence for the effectiveness of drugs to treat anxiety in palliative care patients. These medications have a variety of mechanisms of action, including some drugs where the exact mechanism is unknown. Drug therapy for treatment of anxiety can be considered to work from two distinct approaches. The first is related to the mechanism of action at the level of neurotransmitters in the central nervous system. These include dopamine, gamma amino butyric acid (GABA), noradrenaline and serotonin.
The second approach is aimed at reducing the physical symptoms of anxiety that result from autonomic hyperactivity, such as tremors and palpitations. In some instances, it is these physical manifestations that worsen the cognitive aspects of anxiety, such as an inability to concentrate or sense of foreboding. The use of drugs such as beta-blockers, which slow the heart rate, may reduce or eliminate these physical manifestations and so reduce the overall impact of anxiety. The use of agents to treat physical manifestations may reduce or possibly eliminate the need for agents aimed at altering neurotransmitter systems.
Why it is important to do this review
Anxiety is a distressing condition that is particularly common and troublesome for people dealing with the advanced stages of a life-limiting condition. Excessive anxiety can manifest itself as both physical and emotional symptoms and can reduce a person's ability to cope physically and mentally with the life-limiting condition. Drugs represent one way of allaying a person's anxiety, but choosing the most appropriate drug is dependent on the clinician having access to evidence reviewing the effectiveness of drugs for anxiety in people with life-limiting conditions. To our knowledge prior to the original review in 2004 there had been no systematic search of the international literature for evidence regarding the effectiveness of drug therapy for anxiety disorders in palliative care patients.
Objectives
Methods
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adult palliative care patients (aged 18 years or older) whose symptoms of anxiety were described by the trial authors as beyond what could be seen as normal in this patient group. This could be captured as a score equivalent to clinically significant symptoms on a validated scale, such as the Hamilton Anxiety Rating Scale (HAM-A) (Hamilton 1959) .
We included trials where anxiety was described as a disorder such as adjustment disorder, obsessive-compulsive disorder, phobia, panic disorder, post-traumatic stress disorder or GAD. We sought to verify that symptoms reported as clinically significant were measured using validated scales, and if the population was described as having an anxiety disorder (specifically GAD, substance-induced anxiety, adjustment disorders, obsessive-compulsive disorders, specific phobias such as in response to medical interventions, panic disorders and post-traumatic stress disorder) that it was defined using the International Classification of Disease (ICD) (ICD-10 2010) 77 Drug therapy for symptoms associated with anxiety in adult palliative care patients For the purposes of the review, we defined palliative care patients as people with a progressive, life-limiting illness, no longer responsive to disease-modifying treatments who were thought to be in the last year (or so) of life and were, or would be, eligible to receive palliative care. We did not include studies in which participants were in the last 24 to 48 hours of life. At this time, symptoms of anxiety may also be in part a manifestation of irreversible processes such as multiple organ failure, and treatment may differ from that considered in earlier phases of the disorder.
Types of interventions
Interventions for anxiety included any type of drug therapy, for example, 5-HT3 receptor antagonists, anxiolytic agents, antidepressive agents, antipsychotic and atypical antipsychotic agents, benzodiazepines, butyrophenones, phenothiazines, antihistamines, barbiturates, sedative hypnotics, antiepileptic drugs, ketamine and beta-blockers. We did not include any non-conventional drugs, such as herbal medicines.
Comparator treatments included placebo; another drug therapy or different dose schedule; or a non-drug intervention such as counselling, CBT or relaxation therapies.
Types of outcome measures

Primary outcomes
Search methods for identification of studies
Electronic searches
To identify studies for inclusion in this review, we developed detailed search strategies for each electronic database searched. These were based on the search strategy developed for MEDLINE but revised appropriately for each database. The search strategy used in the original review run in 2003 is reported in Appendix 1 and the search strategies used in the first update of 2012 are presented in Appendix 2, Appendix 3, Appendix 4, Appendix 5, Appendix 6, and Appendix 7. The search strategies used in 2016 for the second update of this review are reported in Appendix 8. We also updated the list of drugs included in the search and re-ran the search for these for all years to May 2016 (see Appendix 9) .
Databases searched
The 77 Drug therapy for symptoms associated with anxiety in adult palliative care patients 5 / 32 outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) , with any disagreements resolved by discussion. We planned to complete a 'Risk of bias' table for each included study using the 'Risk of bias' tool in Review Manager 5 (RevMan 2014).
We aimed to assess the following for each study.
Random sequence generation (checking for possible selection bias). We planned to assess the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We planned to exclude studies using a non-random process (e.g. odd or even date of birth; hospital or clinic record number). Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We planned to assess the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We aimed to exclude studies that did not conceal allocation (e.g. open list). Blinding of participants and personnel (checking for possible performance bias). We planned to assess the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We aimed to assess methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double-dummy technique); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). Studies that were not double-blind were considered to have high risk of bias. Blinding of outcome assessment (checking for possible detection bias). We aimed to assess the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We planned to assess the methods as: low risk of bias (study had a clear statement that outcome assessors were unaware of treatment allocation, and ideally described how this was achieved); unclear risk of bias (study stated that outcome assessors were blind to treatment allocation but lacked a clear statement on how it was achieved). We considered studies where outcome assessment was not blinded as having a high risk of bias. Selective reporting (checking for reporting bias). We aimed to assess whether primary and secondary outcome measures were prespecified and whether these were consistent with those reported. We aimed to assess selective reporting as: low risk of bias (studies reported primary and secondary outcomes); high risk of bias (not all prespecified outcomes reported or only for certain data collection time points). Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We planned to assess the methods used to deal with incomplete data as: low risk of bias (less than 10% of participants did not complete the study or used 'baseline observation carried forward' analysis), or both; unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). Size of study (checking for possible biases confounded by small size). We aimed to assess studies as being at low risk of bias (200 participants or greater per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm)
Measures of treatment effect
We planned to analyse dichotomous data as odds ratios and 95% confidence intervals (CI) and continuous data as mean difference and 95% CI.
Unit of analysis issues
For any RCTs using a cross-over design, we planned to use only data from the first comparative phase prior to cross-over. This decision was based on the possibility of a carry-over of treatment effect from the drug evaluation or a comparative treatment.
Dealing with missing data
For this review, we expected a significant loss to follow-up due to participants' declining health. We planned to report trial attrition rates in the 'Risk of bias' table. This would have included, if available, reasons for attrition per treatment arm. Where study data were missing but might have been available, we planned to contact the authors to obtain missing outcome data where possible. We planned not to exclude trials on the basis of missing data.
Assessment of heterogeneity
If meta-analysis had been possible, we planned to use the I² statistic to assess heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (i.e. I² greater than 50%), we aimed to report it and explore possible causes by performing prespecified subgroup analysis.
Assessment of reporting biases
If meta-analysis had been possible using 10 or more studies, we planned to explore publication bias using Egger's test and by inspection of funnel plots for symmetry.
Data synthesis
We planned to combine study data to provide a pooled effect estimate using a fixed-effect model. If we had found no substantial heterogeneity, we planned to use a random-effects model to check the robustness of the fixed-effect model. If substantial statistical heterogeneity had been observed, we would have used the random-effects model a priori.
If we had found studies that reported a mixture of change-from-baseline and final value scores, we would have only combined data if the studies reported the outcome using the same measurement scale.
Where there were insufficient studies to undertake a meta-analysis, we planned to combine individual studies in a narrative review.
Quality of the evidence
We planned that two review authors (SS and CM) would independently rate the quality of the outcomes. We planned to use the GRADE system to rank the quality of the evidence using the GRADEprofiler Guideline Development Tool software (GRADEpro GDT 2015) , and the guidelines provided in Section 12.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) .
The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence: high: we are very confident that the true effect lies close to that of the estimate of the effect; moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different; low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
We planned to decrease the grade rating by one (-1) or two (-2) if we identified: serious (-1) or very serious (-2) limitation to study quality; important inconsistency (-1); some (-1) or major (-2) uncertainty about directness; imprecise or sparse data (-1); high probability of reporting bias (-1).
'Summary of findings' table
We planned to include six 'Summary of findings' tables to present the main findings for the primary outcome (anxiety) and five secondary outcomes (depression, breathlessness, insomnia, adverse events and withdrawals) in a transparent and simple tabular format. In particular, we planned to include key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data.
Subgroup analysis and investigation of heterogeneity
If three or more studies reported relevant data, we planned to perform the following subgroup analyses: men versus women; mild or moderate anxiety versus severe anxiety; follow-up no greater than one month versus follow-up greater than one month.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the influence of the following factors: excluding unpublished studies; excluding studies considered at high risk of selection bias in terms of adequate allocation concealment, detection bias in terms of blinded outcome assessment and attrition bias due to follow-up of less than 80% of participants in each arm; excluding studies using the following filters: industry funded; non-validated scales used for measuring effect; non-validated diagnostic criteria.
Results
Description of studies
Results of the search
We retrieved 707 potentially relevant studies from the electronic searches and four from other sources for this second update. After removing duplicates, we screened 597 articles for inclusion in the review. We assessed full-text reports of 10 articles. Figure 1 shows the results of the search.
Included studies
Of the 10 full-text reports we assessed for inclusion in this update, we did not identify any studies fulfilling our criteria.
Excluded studies
In this update, we excluded eight reports for the following reasons: five did not include a patient population of interest, specifically it was considered that three included participants with depression and not anxiety ( 
Studies awaiting classification
Two studies provided insufficient information on which to make a decision regarding inclusion, despite attempts to contact the authors for further information (Hart 2012; Usmani 2013) .
Ongoing studies
We did not identify any ongoing studies.
Risk of bias in included studies
We did not identify any relevant studies.
Effects of interventions
Discussion
Summary of main results
We found no studies assessing the effectiveness of drug therapy for treating symptoms of anxiety in adults with a progressive life-limiting illness and who were thought to be in their last year of life. There was a lack of RCTs; while we identified five RCTs, three studies assessed depression rather than anxiety and were thus excluded. There are two studies awaiting classification which may be included in a future update.
Overall completeness and applicability of evidence
We were unable to find any evidence of the effectiveness of drug therapy in the treatment of adult palliative care patients experiencing symptoms of anxiety.
Quality of the evidence
We did not identify any studies to include in the review and thus we are unable to assess the quality of the evidence.
Potential biases in the review process
We undertook a comprehensive search for studies, including searching trials registers and handsearching of conference abstracts with no restrictions on language of study reports. One potential problem we encountered with identifying papers for inclusion was that when first reading a paper the title and abstract might suggest that the study participants were experiencing with anxiety but, on closer inspection, participants were assessed using scales which predominantly measured depression and thus studies did not meet our inclusion criteria.
Agreements and disagreements with other studies or reviews
One systematic review of anxiety therapy for palliative care patients with cancer was undertaken at a similar time to the first update of this Cochrane Review (Nübling 2012). Nübling 2012 included four RCTs in their review but stated that they did not make recommendations for pharmacological treatments based on the findings of these four studies because of "deficiencies in the studies or the analyses." All four studies were excluded from the original Cochrane Review of 2004 as study participants were not considered those of interest for this review. Traeger 2012 examined the evidence for treatment of anxiety in people with cancer and identified two of the studies included in the Nübling 2012 review. Traeger 2012 concluded that finding evidence for effective treatments of anxiety in people with cancer is challenging as anxiety is a complex problem, thus making a diagnosis of anxiety and assessing the effects of treatment is difficult.
Authors' conclusions
Implications for practice
Due to the lack of evidence on the role of drug therapy for treating anxiety in palliative care patients, this review cannot draw any conclusions specific to any medications or drug classes in this patient population. To the best of our knowledge, clinical guidelines from the main health organisations across the world recommend non-drug therapy treatments for anxiety in palliative care patients such as psychological support and intervention (NICE 2004) , in preference to drug treatment except in the last days of life (NICE 2015) . In the case of severe anxiety, guidelines recommend referral to a psychiatrist (National Consensus Project 2009). In addition, there is evidence for the effectiveness of cognitive behavioural therapy as a psychological intervention (Moorey 2009 ).
Until there is evidence indicating harms caused by the drugs currently used in palliative care to manage anxiety, their use is likely to be continued. However, their administration should be based on the severity of symptoms and an assessment of the risk of increased sensitivity to drugs. As addressed in the review, underlying causes for anxiety should be thoroughly evaluated to determine if the cause of a person's anxiety is related to other symptom management or the use of other medications or substances. If appropriate, treating another symptom (e.g. pain) or eliminating an agent that is causing or exacerbating anxiety (e.g. caffeine) may pre-empt the need for another medication to treat anxiety. If drugs are started, they should be at a lower dose than would be prescribed for physically healthy people and any increase should be attempted cautiously and with consideration of other drugs the person may be taking (Roth 2007 
Implications for research
General implications
As there is a lack of evidence of the effectiveness of drug therapy for treating anxiety in people with a life-limiting illness there is a need for research in this topic.
Design
Randomised controlled trials (RCTs), adequately powered and involving more than 200 participants per arm are needed.
Measurement (endpoints)
Depression and anxiety are often measured using the same scale, thus it is necessary that future trials specifically assess and report measures of anxiety. The diagnosis of anxiety should be clearly defined and be a discrete endpoint for the trial. Outcomes need to be assessed using validated tools.
Other
RCTs should follow the CONSORT Statement (Schulz 2010).
Koralewski 2002
Reason for exclusion Not the patient population of interest.
Kronish 2012
Ng 2014
Wald 1993
Yazici 2012
Ziolko 2004
Footnotes RCT: randomised controlled trial.
Characteristics of studies awaiting classification
Hart 2012
Methods Randomised, double-blind, double-dummy placebo-controlled pilot study.
Participants 30 participants with severe respiratory disease.
Interventions
Lorazepam tablets 0.5 mg twice daily with dummy nasal spray up to 4 times daily.
Midazolam 400 mg intranasal 2 sprays up to 4 times daily with placebo tablets.
Outcomes
Borg score, St Georges Respiratory Questionnaire, Hospital Anxiety and Depression scores, Nottingham Activities of Daily Living score.
Notes
Contacted author by e-mail in July and August 2016 to ask for further details but no response received.
Usmani 2013
Methods Intervention study.
Participants
People with chronic obstructive pulmonary disease.
Interventions
Paroxetine 20 mg daily as oral capsule for 4 months.
Placebo pill as oral capsule for 4 months.
Capsules identical in appearance.
Outcomes
Anxiety as measured by Beck Anxiety Inventory, quality of life as assessed by Chronic Respiratory Questionnaire (CRQ).
Notes
Contacted author by e-mail September 2016 to ask for further details but no response received.
Footnotes
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exp Antiepileptic Agents/ carbamazepine or eslicarbazepine or ethosuximide or gabapentin or lacosamide or lamotrigine or levetiracetam or oxcarbazepine or phenobarbital or pregabalin or primidone or phenytoin or retigabine or rufinamide or tiagabine or topiramate or valproate or vigabatrin or zonisamide. #20 ((acebutolol or alimemazine or alprazolam or amitriptyline or atenolol or bisoprolol or bromazepam or buproprion or buspirone or carbamazepine or carisoprodol or carvedilol or celiprolol or clomipramine or chlorazepate or chlordiazepoxide or chlorphenamine or chlorpromazine or citalopram or clemastine or clobazam or clonazepam or co-tenidone or cyproheptadine or diazepam or desipramine or desvenlafaxine or dexmedetomidine or dosulepin or doxepin or duloxetin or escitalopram or esmolol or estazolam or eszopiclone or etizolam or flunitrazepam or fluoxetine or flurazepam or fluvoxamine or gabapentin or halazepam or haloperidol or hydroxyzine or imipramine or isocarboxazid or ketamine or ketazolam or ketotifen or labetalol or lamotrigine or levetiracetam or levomepromaziene or lofepramine or lorazepam or meprobamate or methotrimeprazine or metoprolol or midazolam or milnacipran or mirtazapine or moclobemide or nadolol or nebivolol or nefazodone or nitrazepam or nortriptyline or olanzapine or ondansetron or oxazepam or oxprenolol or paroxetine or perphenazine or phenelzine or phenobarbital or phenytoin or pindolol or prazepam or pregabalin or primidone or promethazine or propranolol or quazepam or ramelteon or risperidone or sertraline or sotalol or temazepam or thioridazine or tiagabine or timolol or topiramate or tranylcypromine or trazodone or triazolam or trifluoperazine or trimipramine or tropisetron or valproate or venlafaxine or vigabatrin or zaleplon or zolpidem)):TI,AB,KY 59251 
